Loading stock data…
Exagen Inc. (XGN)
$4.74+0.16 (+3.49%)
Market OpenUpdated 3:07 PM EDT
Exagen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exagen Inc. in the Healthcare sector is trading at $4.74 with a market capitalization of $110M. Wall Street consensus targets $8.57 (7 analysts), implying a +80.8% move over the next 12 months. The stock is currently 61% below its 52-week high of $12.23, remaining 20.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +80.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.31M↑ | $16.63M↓ | $17.24M↑ | $17.20M↑ | $15.50M |
| Gross Profit | $10.21M↑ | $9.21M↓ | $10.07M↓ | $10.39M↑ | $9.12M |
| Operating Income | -$3.41M↑ | -$4.97M↓ | -$3.10M↓ | -$2.63M↑ | -$3.37M |
| Net Income | -$3.97M↑ | -$4.67M↑ | -$7.09M↓ | -$4.44M↓ | -$3.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$109.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.73%
Volume
Today's trading volume
114,573
Recent News
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets
Exagen is back in focus as analysts refresh their price targets, with the latest models continuing to anchor around an unchanged US$8.67 fair value estimate. Recent Street commentary links these trimmed targets to updated assumptions about valuation, execution risk and the company’s potential growth path, even as the core dollar-based output holds steady. As you read on, you will see how to track these shifts and what to watch as the Exagen story continues to evolve. Stay updated as the Fair...
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts
A week ago, Exagen Inc. ( NASDAQ:XGN ) came out with a strong set of quarterly numbers that could potentially lead to a...
Exagen (XGN) Q1 2026 Earnings Transcript
John Aballi: Good morning, everyone, and thank you for joining us. Today, we reported record first quarter revenue of $17.3 million, up 12% year-over-year and with continued improvement in profitability metrics as we execute our plan. Autoimmune disease is still a category where patients often struggle to get clear answers and clinicians lack the tools to diagnose and treat with confidence in a timely manner.
Exagen Inc. Q1 2026 Earnings Call Summary
Moby summary of Exagen Inc.'s Q1 2026 earnings call